NGEN NervGen Pharma Corp. Common stock
Healthcare$2.08-43.48%ClosedMarket Cap: $168.3M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
108.37
P/S
0.00
EV/EBITDA
-15.42
DCF Value
$0.25
FCF Yield
-4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-17536.8%
ROA
-190.1%
ROIC
-719.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-7.7M | $-1.7M | $— | — |
| Q4 null | $0.00 | Infinity% | $-11.7M | $-31.7M | $— | — |
| FY null | $0.00 | NaN% | $-25.1M | $-44.1M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-4.4M | $-3.0M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-4.8M | $-6.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.2M | $-2.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-4.7M | $-6.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-17.3M | $-16.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-5.3M | $-3.9M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-4.4M | $-5.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-3.7M | $-1.7M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-3.7M | $-6.5M | $-0.11 | — |